28 employees
Inimmune is focused on the discovery and development of novel immunotherapeutics for an array of disease areas.
2016
$22M
from 2 investors over 2 rounds
Inimmune raised $22M on July 9, 2020
Investors: Two Bear Capital
Inimmune raised $593K on October 5, 2018
Investors: National Institute of Allergy and Infectious Diseases (NIAID)